Studies have shown that IGF-1 can effectively improve diabetic cardiomyopathy through its antioxidant and anti-inflammatory effects, as well as by activating the Akt/GSK-3β signaling pathway (62). Here, AKT1 is linked to diabetic cardiomyopathy.